Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2027 Ended June 30, 2026 and Provides Conference Call Information
Elite Pharmaceuticals reported Q1 fiscal 2027 revenue of $32.4 million, a 19.5% decrease from the prior year's record quarter. Operating income fell 65% to $7.5 million, primarily attributed to lower margins realized from sales of the generic Vyvanse product line amid competitive market adjustments.
Key figures
- Revenue
- $32.4 million
- Revenue Yoy
- -19.5%
- Net income
- $5.9 million
- Operating income
- $7.5 million
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.